EyeGate announce 1-for-15 reverse stock split effective August 30.
EyeGate Pharmaceuticals announced a reverse stock split of its shares of common stock at a ratio of 1-for-15. Upon the commencement of trading on August 30, 2019, the company's common stock will begin trading on a post-split basis. The reverse stock split is being implemented primarily to bring the company into compliance with the minimum bid price requirements for maintaining its listing on The Nasdaq Capital Market. To comply with this requirement, the closing bid price of the company's common stock must be at least $1 per share for a minimum of 10 consecutive business days prior to September 16, 2019.
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 29, 2019|
|Previous Article:||DA Davidson views New Relic's issues as fixable after management meetings.|
|Next Article:||Facebook Business launches lead generation in Messenger.|